These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

788 related articles for article (PubMed ID: 30594222)

  • 1. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
    Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial.
    Koga T; Hagimori N; Sato S; Morimoto S; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jan; 99(1):e18328. PubMed ID: 31895769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever.
    Koga T; Sato S; Hagimori N; Yamamoto H; Ishimura M; Yasumi T; Kirino Y; Ikeda K; Yachie A; Migita K; Kishida D; Atsumi T; Kawakami A
    Clin Exp Rheumatol; 2022 Sep; 40(8):1535-1542. PubMed ID: 36106542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X; Tian F; Wu B; Xu T
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
    Hashkes PJ; Spalding SJ; Giannini EH; Huang B; Johnson A; Park G; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright DA; Kastner DL; Lovell DJ
    Ann Intern Med; 2012 Oct; 157(8):533-41. PubMed ID: 23070486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy in familial Mediterranean fever.
    Koga T; Migita K; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.
    Ben-Zvi I; Livneh A
    Isr Med Assoc J; 2014 May; 16(5):271-3. PubMed ID: 24979828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
    Front Immunol; 2020; 11():971. PubMed ID: 32670263
    [No Abstract]   [Full Text] [Related]  

  • 11. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.
    Ugurlu S; Hacioglu A; Adibnia Y; Hamuryudan V; Ozdogan H
    Orphanet J Rare Dis; 2017 May; 12(1):105. PubMed ID: 28558744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2015 Mar; (3):CD010893. PubMed ID: 25791871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Ben-Zvi I; Kukuy O; Giat E; Pras E; Feld O; Kivity S; Perski O; Bornstein G; Grossman C; Harari G; Lidar M; Livneh A
    Arthritis Rheumatol; 2017 Apr; 69(4):854-862. PubMed ID: 27860460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial.
    Koga T; Hagimori N; Takemori S; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e20710. PubMed ID: 32791665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF.
    Hashkes PJ; Huang B
    Isr Med Assoc J; 2015 Mar; 17(3):137-40. PubMed ID: 25946762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
    J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?
    Erden A; Batu ED; Sarı A; Sönmez HE; Armagan B; Demir S; Fırat E; Bilginer Y; Bilgen SA; Karadağ Ö; Kalyoncu U; Kiraz S; Ertenli I; Özen S; Akdogan A
    Clin Exp Rheumatol; 2018; 36(6 Suppl 115):97-102. PubMed ID: 30418112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review.
    Demirkaya E; Erer B; Ozen S; Ben-Chetrit E
    Rheumatol Int; 2016 Mar; 36(3):325-31. PubMed ID: 26687683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
    Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
    Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.